

Healthcare Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Services (Contract Development, Contract Manufacturing), By Region (Europe, APAC), And Segment Forecasts, 2024 - 2030

<https://marketpublishers.com/r/H5517FB1DAE9EN.html>

Date: July 2024

Pages: 145

Price: US\$ 5,950.00 (Single User License)

ID: H5517FB1DAE9EN

Abstracts

This report can be delivered to the clients within 3 Business Days

Healthcare Contract Development and Manufacturing Organization Market Growth & Trends

The global healthcare contract development and manufacturing organization market size is expected to reach USD 471.0 billion by 2030, growing at a CAGR of 9.68% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is expected to show lucrative growth due to rising outsourcing trends and increasing R&D expenditure.

Healthcare contract development and manufacturing organization (CDMO) provide outsourcing services to various pharmaceutical industries on a contract basis. An increase in outsourcing by pharmaceutical companies, expansions in the pharmaceutical industry, and the support of CDMOs in reducing operational and capital expenses are some of the major factors anticipated to propel the market growth in the forecast period.

In addition, growing requirement among pharmaceutical and medical device companies to follow stringent timelines has increased the demand for outsourcing development and manufacturing activities to CDMOs. Further, due to the increasing demand for medical devices in emerging countries, various companies are shifting their focus on

research and development activities for medical device contract development and manufacturing. Over the past 10 years, several pharmaceutical companies have turned to CMOs, CROs, and CDMOs to assist in pre-formulation and development & manufacturing of their novel innovations. Outsourcing is a high growth market, and most spending is focused on early development.

Around 75% of new drug pipelines come from small- and mid-sized biopharmaceutical companies. These companies have high profit margins, which make them easy targets for healthcare providers who are trying to reduce costs. Thus, instead of investing in establishing their own infrastructure, it is profitable for these companies to outsource services to third-party organizations that have expertise and the required equipment. Several pharmaceutical companies are seeking outsourced services for optimizing the development of their molecules. Furthermore, a large number of CDMO collaborations, expansions, mergers & acquisitions, and other strategic initiatives undertaken by market players operating in the country are anticipated to boost the market. For instance, In March 2023, Remedium Bio, a U.S.-based biotechnology company, entered into a collaboration agreement with Exothera, a Belgium-based CDMO, to scale up the production of Remedium's lead gene therapy drug candidate, AAV2-FGF18 in the treatment of osteoarthritis. Similarly, in January 2024, Enzene Biosciences, a subsidiary of Alkem Labs announced the manufacturing site in the U.S. Such innovations are anticipated to drive the market.

However, increasing logistic costs, serialization issues faced by healthcare organizations, and the threat of infringement of Intellectual Property (IP) rights are anticipated to restrain the market growth for healthcare contract development & manufacturing organization over the forecast period.

Healthcare Contract Development and Manufacturing Organization Market Report Highlights

Based on services, the contract manufacturing segment dominated the market with a revenue share of 73.50% in 2023 due to increase in the outsourcing of manufacturing services by pharmaceutical and medical device companies. In addition, cost-effectiveness, and the increasing number of CMOs are some of the key factors that are positively affecting the market growth.

By small molecule contract development sub-segment, the preclinical/segment is expected to register the highest CAGR.

of 9.53% in the forecast period due to the rising pipeline of novel therapeutics

North America dominated the healthcare contract development and manufacturing organization industry with the largest revenue share of 40.91% in 2023. High shares of the region are majorly due to the presence of a large number of actively functioning CROs and CMOs in the region, especially across the U.S.

Contents

CHAPTER 1. RESEARCH METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
 - 1.1.1. Segment Definitions
 - 1.1.2. Services
- 1.2. Regional Scope
- 1.3. Estimates And Forecast Timeline
- 1.4. Objectives
 - 1.4.1. Objective-1
 - 1.4.2. Objective-2
 - 1.4.3. Objective-3
- 1.5. Research Methodology
- 1.6. Information Procurement
 - 1.6.1. Purchased Database
 - 1.6.2. GVR's Internal Database
 - 1.6.3. Secondary Sources
 - 1.6.4. Primary Research
- 1.7. Information Or Data Analysis
 - 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
 - 1.9.1. Commodity Flow Analysis
 - 1.9.2. Parent Market Analysis
- 1.10. List Of Secondary Sources
- 1.11. List Of Abbreviations

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights

CHAPTER 3. HEALTHCARE CDMO MARKET VARIABLES, TRENDS & SCOPE

- 3.1. Market Lineage Outlook
 - 3.1.1. Parent Market Outlook
 - 3.1.2. Related/Ancillary Market Outlook

3.2. Product Pipeline Analysis, by Service

3.3. Market Dynamics

3.3.1. Market Driver Analysis

3.3.1.1. Increasing Outsourcing Services By Pharmaceutical Companies

3.3.1.2. Rising Investment In R&D

3.3.1.3. Growing Pharmaceutical Industry

3.3.1.4. Increasing Demand For One-Stop-Shop CDMOs

3.3.2. Market Restraint Analysis

3.3.2.1. Compliance Issues While Outsourcing

3.3.2.2. Changing Scenarios In Developing Countries

3.3.2.3. Regulatory And Legal Compliance

3.4. Healthcare CDMO Market Analysis Tools

3.4.1. Industry Analysis - Porter's

3.4.1.1. Supplier Power

3.4.1.2. Buyer Power

3.4.1.3. Substitution Threat

3.4.1.4. Threat Of New Entrant

3.4.1.5. Competitive Rivalry

3.4.2. PESTEL Analysis

3.4.3. COVID-19 Impact Analysis

3.4.4. Major Deals & Strategic Alliances Analysis

3.4.4.1. Mergers & Acquisitions

3.4.4.2. Geographic Expansions

3.4.4.3. Partnerships

3.4.4.4. Launch

3.4.4.5. Collaborations

CHAPTER 4. HEALTHCARE CDMO MARKET: SERVICES ESTIMATES & TREND ANALYSIS

4.1. Healthcare CDMO Market, By Services: Segment Dashboard

4.2. Healthcare CDMO Market, By Services: Movement Analysis

4.3. Healthcare CDMO Market Estimates & Forecasts, By Services, 2018 - 2030

4.3.1. Contract Development

4.3.1.1. Contract Development Healthcare CDMO Market, 2018 to 2030 (USD Million)

4.3.1.2. Small Molecule

4.3.1.2.1. Small Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)

4.3.1.2.2. Preclinical

- 4.3.1.2.2.1. Preclinical Healthcare CDMO Market, 2018 to 2030 (USD Million)
- 4.3.1.2.2.2. Bioanalysis and DMPK studies
 - 4.3.1.2.2.2.1. Bioanalysis and DMPK studies Healthcare CDMO Market, 2018 to 2030 (USD Million)
- 4.3.1.2.2.3. Toxicology Testing
 - 4.3.1.2.2.3.1. Toxicology Testing Healthcare CDMO Market, 2018 to 2030 (USD Million)
- 4.3.1.2.2.4. Other Preclinical Services
 - 4.3.1.2.2.4.1. Other Preclinical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
- 4.3.1.2.3. Clinical
 - 4.3.1.2.3.1. Clinical Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.1.2.3.2. Phase I
 - 4.3.1.2.3.2.1. Phase I Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.1.2.3.3. Phase II
 - 4.3.1.2.3.3.1. Phase II Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.1.2.3.4. Phase III
 - 4.3.1.2.3.4.1. Phase III Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.1.2.3.5. Phase IV
 - 4.3.1.2.3.5.1. Phase IV Healthcare CDMO Market, 2018 to 2030 (USD Million)
- 4.3.1.2.4. Laboratory Services
 - 4.3.1.2.4.1. Laboratory Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.1.2.4.2. Bioanalytical Services
 - 4.3.1.2.4.2.1. Bioanalytical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.1.2.4.3. Analytical Services
 - 4.3.1.2.4.3.1. Analytical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
- 4.3.1.3. Large Molecule
 - 4.3.1.3.1. Large Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.1.3.2. Cell line development
 - 4.3.1.3.2.1. Cell line development Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.1.3.3. Process Development
 - 4.3.1.3.3.1. Process Development Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.1.3.3.2. Upstream
 - 4.3.1.3.3.2.1. Upstream Healthcare CDMO Market, 2018 to 2030 (USD Million)

- 4.3.1.3.3.2.2. Microbial
 - 4.3.1.3.3.2.2.1. Microbial Healthcare CDMO Market, 2018 to 2030 (USD Million)
- 4.3.1.3.3.2.3. Mammalian
 - 4.3.1.3.3.2.3.1. Mammalian Healthcare CDMO Market, 2018 to 2030 (USD Million)
- 4.3.1.3.3.2.4. Others
 - 4.3.1.3.3.2.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
- 4.3.1.3.3.3. Downstream
 - 4.3.1.3.3.3.1. Downstream Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.1.3.3.3.2. MABs
 - 4.3.1.3.3.3.2.1. MABs Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.1.3.3.3.3. Recombinant Proteins
 - 4.3.1.3.3.3.3.1. Recombinant Proteins Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.1.3.3.3.4. Others
 - 4.3.1.3.3.3.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
- 4.3.2. Contract Manufacturing
 - 4.3.2.1. Contract Manufacturing Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.2.2. Small Molecule
 - 4.3.2.2.1. Small Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.2.3. Large Molecule
 - 4.3.2.3.1. Large Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.2.3.2. MABs
 - 4.3.2.3.2.1. MABs Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.2.3.3. Recombinant Proteins
 - 4.3.2.3.3.1. Recombinant Proteins Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.2.3.4. Others
 - 4.3.2.3.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.2.4. High Potency API
 - 4.3.2.4.1. High Potency API Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.2.5. Finished Dose Formulations
 - 4.3.2.5.1. Finished Dose Formulations Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.2.5.2. Solid Dose Formulation
 - 4.3.2.5.2.1. Solid Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
 - 4.3.2.5.3. Liquid Dose Formulation

4.3.2.5.3.1. Liquid Dose Formulation Healthcare CDMO Market, 2018 to 2030
(USD Million)

4.3.2.5.4. Injectable Dose Formulation

4.3.2.5.4.1. Injectable Dose Formulation Healthcare CDMO Market, 2018 to 2030
(USD Million)

4.3.2.6. Medical Device

4.3.2.6.1. Medical Device Healthcare CDMO Market, 2018 to 2030 (USD Million)

4.3.2.6.2. Class I

4.3.2.6.2.1. Class I Healthcare CDMO Market, 2018 to 2030 (USD Million)

4.3.2.6.3. Class II

4.3.2.6.3.1. Class II Healthcare CDMO Market, 2018 to 2030 (USD Million)

4.3.2.6.4. Class III

4.3.2.6.4.1. Class III Healthcare CDMO Market, 2018 to 2030 (USD Million)

CHAPTER 5. HEALTHCARE CDMO MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

5.1. Regional Market Share Analysis, 2022 & 2030

5.2. Regional Market Dashboard

5.3. Global Regional Market Snapshot

5.4. North America

5.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)

5.4.2. U.S.

5.4.2.1. Key Country Dynamics

5.4.2.2. Competitive Scenario

5.4.2.3. Regulatory Framework

5.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030

5.4.3. Canada

5.4.3.1. Key Country Dynamics

5.4.3.2. Competitive Scenario

5.4.3.3. Regulatory Framework

5.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030

5.5. Europe

5.5.1. UK

5.5.1.1. Key Country Dynamics

5.5.1.2. Competitive Scenario

5.5.1.3. Regulatory Framework

5.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030

5.5.2. Germany

- 5.5.2.1. Key Country Dynamics
- 5.5.2.2. Competitive Scenario
- 5.5.2.3. Regulatory Framework
- 5.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
- 5.5.3. France
 - 5.5.3.1. Key Country Dynamics
 - 5.5.3.2. Competitive Scenario
 - 5.5.3.3. Regulatory Framework
 - 5.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
- 5.5.4. Italy
 - 5.5.4.1. Key Country Dynamics
 - 5.5.4.2. Competitive Scenario
 - 5.5.4.3. Regulatory Framework
 - 5.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
- 5.5.5. Spain
 - 5.5.5.1. Key Country Dynamics
 - 5.5.5.2. Competitive Scenario
 - 5.5.5.3. Regulatory Framework
 - 5.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
- 5.5.6. Denmark
 - 5.5.6.1. Key Country Dynamics
 - 5.5.6.2. Competitive Scenario
 - 5.5.6.3. Regulatory Framework
 - 5.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
- 5.5.7. Sweden
 - 5.5.7.1. Key Country Dynamics
 - 5.5.7.2. Competitive Scenario
 - 5.5.7.3. Regulatory Framework
 - 5.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
- 5.5.8. Norway
 - 5.5.8.1. Key Country Dynamics
 - 5.5.8.2. Competitive Scenario
 - 5.5.8.3. Regulatory Framework
 - 5.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
- 5.5.9. Netherlands
 - 5.5.9.1. Key Country Dynamics
 - 5.5.9.2. Competitive Scenario
 - 5.5.9.3. Regulatory Framework
 - 5.5.9.4. Netherlands Market Estimates and Forecasts, 2018 - 2030

5.5.10. Belgium

5.5.10.1. Key Country Dynamics

5.5.10.2. Competitive Scenario

5.5.10.3. Regulatory Framework

5.5.10.4. Belgium Market Estimates and Forecasts, 2018 - 2030

5.6. Asia Pacific

5.6.1. Japan

5.6.1.1. Key Country Dynamics

5.6.1.2. Competitive Scenario

5.6.1.3. Regulatory Framework

5.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030

5.6.2. India

5.6.2.1. Key Country Dynamics

5.6.2.2. Competitive Scenario

5.6.2.3. Regulatory Framework

5.6.2.4. India Market Estimates and Forecasts, 2018 - 2030

5.6.3. China

5.6.3.1. Key Country Dynamics

5.6.3.2. Competitive Scenario

5.6.3.3. Regulatory Framework

5.6.3.4. China Market Estimates and Forecasts, 2018 - 2030

5.6.4. South Korea

5.6.4.1. Key Country Dynamics

5.6.4.2. Competitive Scenario

5.6.4.3. Regulatory Framework

5.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030

5.6.5. Australia

5.6.5.1. Key Country Dynamics

5.6.5.2. Competitive Scenario

5.6.5.3. Regulatory Framework

5.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030

5.6.6. Thailand

5.6.6.1. Key Country Dynamics

5.6.6.2. Competitive Scenario

5.6.6.3. Regulatory Framework

5.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030

5.6.7. Malaysia

5.6.7.1. Key Country Dynamics

5.6.7.2. Competitive Scenario

- 5.6.7.3. Regulatory Framework
- 5.6.7.4. Malaysia Market Estimates and Forecasts, 2018 - 2030
- 5.6.8. New Zealand
 - 5.6.8.1. Key Country Dynamics
 - 5.6.8.2. Competitive Scenario
 - 5.6.8.3. Regulatory Framework
 - 5.6.8.4. New Zealand Market Estimates and Forecasts, 2018 - 2030
- 5.6.9. Singapore
 - 5.6.9.1. Key Country Dynamics
 - 5.6.9.2. Competitive Scenario
 - 5.6.9.3. Regulatory Framework
 - 5.6.9.4. Singapore Market Estimates and Forecasts, 2018 - 2030
- 5.6.10. Philippines
 - 5.6.10.1. Key Country Dynamics
 - 5.6.10.2. Competitive Scenario
 - 5.6.10.3. Regulatory Framework
 - 5.6.10.4. Philippines Market Estimates and Forecasts, 2018 - 2030
- 5.7. Latin America
 - 5.7.1. Brazil
 - 5.7.1.1. Key Country Dynamics
 - 5.7.1.2. Competitive Scenario
 - 5.7.1.3. Regulatory Framework
 - 5.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
 - 5.7.2. Mexico
 - 5.7.2.1. Key Country Dynamics
 - 5.7.2.2. Competitive Scenario
 - 5.7.2.3. Regulatory Framework
 - 5.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
 - 5.7.3. Argentina
 - 5.7.3.1. Key Country Dynamics
 - 5.7.3.2. Competitive Scenario
 - 5.7.3.3. Regulatory Framework
 - 5.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
 - 5.7.4. Colombia
 - 5.7.4.1. Key Country Dynamics
 - 5.7.4.2. Competitive Scenario
 - 5.7.4.3. Regulatory Framework
 - 5.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030
 - 5.7.5. Chile

- 5.7.5.1. Key Country Dynamics
- 5.7.5.2. Competitive Scenario
- 5.7.5.3. Regulatory Framework
- 5.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030

5.8. MEA

- 5.8.1. South Africa
 - 5.8.1.1. Key Country Dynamics
 - 5.8.1.2. Competitive Scenario
 - 5.8.1.3. Regulatory Framework
 - 5.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
- 5.8.2. Saudi Arabia
 - 5.8.2.1. Key Country Dynamics
 - 5.8.2.2. Competitive Scenario
 - 5.8.2.3. Regulatory Framework
 - 5.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
- 5.8.3. UAE
 - 5.8.3.1. Key Country Dynamics
 - 5.8.3.2. Competitive Scenario
 - 5.8.3.3. Regulatory Framework
 - 5.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
- 5.8.4. Kuwait
 - 5.8.4.1. Key Country Dynamics
 - 5.8.4.2. Competitive Scenario
 - 5.8.4.3. Regulatory Framework
 - 5.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030
- 5.8.5. Israel
 - 5.8.5.1. Key Country Dynamics
 - 5.8.5.2. Competitive Scenario
 - 5.8.5.3. Regulatory Framework
 - 5.8.5.4. Israel Market Estimates and Forecasts, 2018 - 2030

CHAPTER 6. COMPETITIVE LANDSCAPE

- 6.1. Market Participant Categorization
 - 6.1.1. Innovators
 - 6.1.2. Market Leaders
 - 6.1.3. Emerging Players
 - 6.1.4. Company Market Share Analysis, 2022
- 6.2. Company Profiles

- 6.2.1. Catalent Inc.
 - 6.2.1.1. Company Overview
 - 6.2.1.2. Financial Performance
 - 6.2.1.3. Service Benchmarking
 - 6.2.1.4. Strategic Initiatives
- 6.2.2. Lonza
 - 6.2.2.1. Company Overview
 - 6.2.2.2. Financial Performance
 - 6.2.2.3. Service Benchmarking
 - 6.2.2.4. Strategic Initiatives
- 6.2.3. Recipharm AB
 - 6.2.3.1. Company Overview
 - 6.2.3.2. Financial Performance
 - 6.2.3.3. Service Benchmarking
 - 6.2.3.4. Strategic Initiatives
- 6.2.4. Siegfried Holding AG
 - 6.2.4.1. Company Overview
 - 6.2.4.2. Financial Performance
 - 6.2.4.3. Service Benchmarking
 - 6.2.4.4. Strategic Initiatives
- 6.2.5. Thermo Fisher Scientific, Inc
 - 6.2.5.1. Company Overview
 - 6.2.5.2. Financial Performance
 - 6.2.5.3. Service Benchmarking
 - 6.2.5.4. Strategic Initiatives
- 6.2.6. Labcorp Drug Development
 - 6.2.6.1. Company Overview
 - 6.2.6.2. Financial Performance
 - 6.2.6.3. Service Benchmarking
 - 6.2.6.4. Strategic Initiatives
- 6.2.7. Jabil Inc
 - 6.2.7.1. Company Overview
 - 6.2.7.2. Financial Performance
 - 6.2.7.3. Service Benchmarking
 - 6.2.7.4. Strategic Initiatives
- 6.2.8. Syngene International Limited
 - 6.2.8.1. Company Overview
 - 6.2.8.2. Financial Performance
 - 6.2.8.3. Service Benchmarking

- 6.2.8.4. Strategic Initiatives
- 6.2.9. IQVIA Inc.
 - 6.2.9.1. Company Overview
 - 6.2.9.2. Financial Performance
 - 6.2.9.3. Service Benchmarking
 - 6.2.9.4. Strategic Initiatives
- 6.2.10. Almac Group
 - 6.2.10.1. Company Overview
 - 6.2.10.2. Financial Performance
 - 6.2.10.3. Service Benchmarking
 - 6.2.10.4. Strategic Initiatives
- 6.2.11. Ajinomoto Bio-Pharma
 - 6.2.11.1. Company Overview
 - 6.2.11.2. Financial Performance
 - 6.2.11.3. Service Benchmarking
 - 6.2.11.4. Strategic Initiatives
- 6.2.12. Adare Pharma Solutions
 - 6.2.12.1. Company Overview
 - 6.2.12.2. Financial Performance
 - 6.2.12.3. Service Benchmarking
 - 6.2.12.4. Strategic Initiatives
- 6.2.13. Alcami Corporation
 - 6.2.13.1. Company Overview
 - 6.2.13.2. Financial Performance
 - 6.2.13.3. Service Benchmarking
 - 6.2.13.4. Strategic Initiatives
- 6.2.14. Vetter Pharma International
 - 6.2.14.1. Company Overview
 - 6.2.14.2. Financial Performance
 - 6.2.14.3. Service Benchmarking
 - 6.2.14.4. Strategic Initiatives

CHAPTER 7. KOL COMMENTARY/RECOMMENDATIONS

List Of Tables

LIST OF TABLES

Table 1 List of Secondary Sources

Table 2 List of Abbreviations

Table 3 Global Healthcare CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION Market, By Region 2018 - 2030 (USD Million)

Table 4 Global Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 5 North America Healthcare Contract Development and Manufacturing Organization Market, By Country, 2018 - 2030 (USD Million)

Table 6 North America Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 7 U.S. Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 8 Canada Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 9 Europe Healthcare Contract Development and Manufacturing Organization Market, By Country, 2018 - 2030 (USD Million)

Table 10 Europe Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 11 U.K. Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 12 Germany Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 13 France Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 14 Italy Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 15 Spain Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 16 Netherlands Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 17 Belgium Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 18 Denmark Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 19 Norway Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 20 Sweden Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 21 Asia Pacific Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 22 China Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 23 Japan Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 24 India Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 25 Australia Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 26 South Korea Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 27 Malaysia Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 28 New Zealand Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 29 Singapore Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 30 Philippines Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 31 Thailand Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 32 Latin America Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 33 Brazil Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 34 Mexico Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 35 Argentina Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 36 Colombia Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 37 Chile Healthcare Contract Development and Manufacturing Organization Market, By Services, 2018 - 2030 (USD Million)

Table 38 Middle East & Africa Healthcare Contract Development and Manufacturing

Organization Market, By Services, 2018 - 2030 (USD Million)

Table 39 South Africa Healthcare Contract Development and Manufacturing

Organization Market, By Services, 2018 - 2030 (USD Million)

Table 40 Saudi Arabia Healthcare Contract Development and Manufacturing

Organization Market, By Services, 2018 - 2030 (USD Million)

Table 41 UAE Healthcare Contract Development and Manufacturing Organization

Market, By Services, 2018 - 2030 (USD Million)

Table 42 Israel Healthcare Contract Development and Manufacturing Organization

Market, By Services, 2018 - 2030 (USD Million)

Table 43 Kuwait Healthcare Contract Development and Manufacturing Organization

Market, By Services, 2018 - 2030 (USD Million)

List Of Figures

LIST OF FIGURES

- Fig. 1 Global roasted coffee market segmentation
- Fig. 2 Information procurement
- Fig. 3 Primary research pattern
- Fig. 4 Primary research approaches
- Fig. 5 Primary research process
- Fig. 6 Market snapshot
- Fig. 7 Product type segment snapshot
- Fig. 8 Distribution channel segment snapshot
- Fig. 9 Competitive landscape snapshot
- Fig. 10 Global coffee market value, 2023 (USD Billion)
- Fig. 11 Global roasted coffee market - Penetration & growth prospect mapping
- Fig. 12 Roasted coffee market- Industry value chain analysis
- Fig. 13 Roasted coffee market profit margin analysis
- Fig. 14 Roasted coffee market dynamics
- Fig. 15 Annual coffee consumption (kg per capita) by European countries (2022)
- Fig. 16 Number of Starbucks stores worldwide (2010 to 2022)
- Fig. 17 Number of cafes and coffee shops in Europe, 2020
- Fig. 18 Roasted coffee market: Porter's five force analysis
- Fig. 19 Roadmap of the global roasted coffee market
- Fig. 20 Roasted coffee consumption, by age group, 2023
- Fig. 21 Roasted coffee consumption, by gender, in U.S. 2023
- Fig. 22 Factors influencing the buying decisions of roasted coffee
- Fig. 23 Roasted coffee market, by Product type: Key takeaways
- Fig. 24 Roasted coffee market, by type: Market share, 2023 & 2030
- Fig. 25 Arabica roasted coffee market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 26 Robusta roasted coffee market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 27 Roasted coffee market, by distribution channel: Key takeaways
- Fig. 28 Roasted coffee market, by distribution channel: Market share, 2023 & 2030
- Fig. 29 Roasted coffee market estimates & forecasts, through B2B distribution channel, 2018 - 2030 (USD Million)
- Fig. 30 Roasted coffee market estimates & forecasts, through B2C distribution channel, 2018 - 2030 (USD Million)
- Fig. 31 Roasted coffee market estimates & forecasts, through hypermarkets & supermarkets, 2018 - 2030 (USD Million)

Fig. 32 Roasted coffee market estimates & forecasts, through convenience stores, 2018 - 2030 (USD Million)

Fig. 33 Roasted coffee market estimates & forecasts, through online channel, 2018 - 2030 (USD Million)

Fig. 34 Roasted coffee market estimates & forecasts, through other B2C channels, 2018 - 2030 (USD Million)

Fig. 35 Roasted coffee market revenue, by region, 2023 & 2030 (USD Million)

Fig. 36 Regional marketplace: Key takeaways

Fig. 37 Regional marketplace: Key takeaways

Fig. 38 North America roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 39 U.S. roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 40 Canada roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 41 Mexico roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 42 Europe roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 43 U.K. roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 44 Germany roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 45 France roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 46 Italy roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 47 Spain roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 48 Asia Pacific roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 49 China roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 50 Japan roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 51 India roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 52 Central & South America roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 53 Brazil roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 54 Middle East & Africa roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 55 Ethiopia roasted coffee market estimates & forecast, 2018 - 2030 (USD Million)

Fig. 56 Key company categorization

Fig. 57 Company market share analysis, 2023

Fig. 58 Strategic framework of the roasted coffee market

I would like to order

Product name: Healthcare Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Services (Contract Development, Contract Manufacturing), By Region (Europe, APAC), And Segment Forecasts, 2024 - 2030

Product link: <https://marketpublishers.com/r/H5517FB1DAE9EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H5517FB1DAE9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970